|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||4.39 / 9.29|
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
We closed out our position in OraSure Technologies for an average gain of 105% gain.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2016 financial and...
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
We used a price decline to add to our position in TherapeuticsMD this week.
Investors in TherapeuticsMD, Inc. saw new options become available today, for the September 15th expiration.
This week we'll get regional economic and housing data, a GDP report plus fourth-quarter earnings.
We’d look to purchase Builders FirstSource, Jive Software and TherapeuticsMD on near-term declines.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will host an Investor Day on Wednesday, March 1, 2017, in New York City.
We would consider adding to TherapeuticsMD on the next market decline and booking profits in ON Semiconductor into a rally.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the publication of two manuscripts detailing results of the company's phase 3 Rejoice Trial in Menopause: The Journal of The...
We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.
TherapeuticsMD is up 9.7% in the first two trading days of 2017, and we're maintaining our $12.50 price target.
Sirius, Medtronic and Carlyle could be money makers in 2017, says Jim Cramer.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will present at the 35 th Annual J.
We closed out a number of holdings for big gains in 2016, including McDermott, Cott and CECO Environmental.
We didn't make any trades this week but are keeping 40% of the portfolio in cash to add names as opportunities arise.
We bought more TherapeuticsMD and Yamana Gold using proceeds from the sale of some Orasure shares.
Cantor Fitzgerald initiated coverage of the company overnight with $34 price target.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company headquartered in Boca Raton, announced the company's participation in the 2016 BioFlorida Conference to be held in Jacksonville from December...
We bought shares of TherapeuticsMD but still have a large portion of the portfolio in cash.
With a stock up 400%, what's not to like about Pioneer Natural Resources? Cramer says.
Stocks once considered free of risks aren't any longer, Cramer warns.